IL110045A - Pharmaceutical compositions containing oligopeptides for combating AIDS and ARC and for immune stimulation and certain such novel oligopeptides - Google Patents

Pharmaceutical compositions containing oligopeptides for combating AIDS and ARC and for immune stimulation and certain such novel oligopeptides

Info

Publication number
IL110045A
IL110045A IL11004594A IL11004594A IL110045A IL 110045 A IL110045 A IL 110045A IL 11004594 A IL11004594 A IL 11004594A IL 11004594 A IL11004594 A IL 11004594A IL 110045 A IL110045 A IL 110045A
Authority
IL
Israel
Prior art keywords
oligopeptides
arc
certain
pharmaceutical compositions
compositions containing
Prior art date
Application number
IL11004594A
Other languages
English (en)
Other versions
IL110045A0 (en
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of IL110045A0 publication Critical patent/IL110045A0/xx
Publication of IL110045A publication Critical patent/IL110045A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A61K38/105—Bombesin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/13—Luteinizing hormone-releasing hormone; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL11004594A 1993-06-18 1994-06-17 Pharmaceutical compositions containing oligopeptides for combating AIDS and ARC and for immune stimulation and certain such novel oligopeptides IL110045A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4320201A DE4320201A1 (de) 1993-06-18 1993-06-18 Verwendung von Cetrorelix und weiteren Nona- und Dekapeptiden zur Herstellung eines Arzneimittels zur Bekämpfung von Aids und zur Wachstumsstimulation

Publications (2)

Publication Number Publication Date
IL110045A0 IL110045A0 (en) 1994-10-07
IL110045A true IL110045A (en) 2000-06-01

Family

ID=6490614

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11004594A IL110045A (en) 1993-06-18 1994-06-17 Pharmaceutical compositions containing oligopeptides for combating AIDS and ARC and for immune stimulation and certain such novel oligopeptides

Country Status (24)

Country Link
US (1) US5985834A (no)
EP (1) EP0703786B1 (no)
JP (1) JPH08511784A (no)
KR (1) KR100352541B1 (no)
CN (1) CN1136915C (no)
AT (1) ATE213164T1 (no)
AU (1) AU688315B2 (no)
BR (1) BR9406893A (no)
CZ (1) CZ285997B6 (no)
DE (2) DE4320201A1 (no)
DK (1) DK0703786T3 (no)
ES (1) ES2172533T3 (no)
FI (1) FI113008B (no)
HU (1) HUT73673A (no)
IL (1) IL110045A (no)
NO (1) NO320945B1 (no)
PL (1) PL175580B1 (no)
PT (1) PT703786E (no)
RU (1) RU2154492C2 (no)
SG (1) SG52240A1 (no)
TW (1) TW370532B (no)
UA (1) UA41938C2 (no)
WO (1) WO1995000168A1 (no)
ZA (1) ZA944347B (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843901A (en) * 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5916582A (en) * 1996-07-03 1999-06-29 Alza Corporation Aqueous formulations of peptides
US5932547A (en) 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
US5981489A (en) * 1996-07-18 1999-11-09 Alza Corporation Non-aqueous protic peptide formulations
DE19728737C1 (de) * 1997-07-04 1999-02-11 Johannes Christian Groeninghen Verfahren zur Erkennung und Bestimmung von GnRH-Rezeptoren und die Verwendung von GnRH-Agonisten und GnRH-Antagonisten zur Behandlung eines Tumors ausgehend vom Hirn und/oder Nervensystem und/oder den Hirnhäuten
US8962558B2 (en) 1997-07-04 2015-02-24 Johannes C. van Groeninghen Methods for reducing GnRH-positive tumor cell proliferation using the GnRH antagonist IN3
NZ521273A (en) * 2000-03-14 2005-01-28 Zentaris Gmbh Novel LHRH-antagonists, production and use thereof as medicament for hormone-dependant tumors, endometriosis, beign prostate hyperplasia and fertility disorders
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
US20040138138A1 (en) * 2001-08-02 2004-07-15 Jurgen Engel Use of LHRH-antagonists in doses that do not cause castration for the improvement of T-cell mediated immunity
IL147138A0 (en) * 2001-12-17 2002-08-14 Yeda Res & Dev Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
US7250514B1 (en) * 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20110129532A1 (en) * 2008-05-29 2011-06-02 Isr Immune System Regulation Ab Method and means for treating viral disease, in particular hiv/aids
CN103695530B (zh) 2008-07-07 2016-05-25 牛津纳米孔技术有限公司 酶-孔构建体
WO2010004273A1 (en) 2008-07-07 2010-01-14 Oxford Nanopore Technologies Limited Base-detecting pore
GB0820927D0 (en) 2008-11-14 2008-12-24 Isis Innovation Method
EP2391655B1 (en) * 2009-01-30 2017-10-11 Oxford Nanopore Technologies Limited Hybridization linkers
AU2010209528B2 (en) 2009-01-30 2015-10-01 Oxford Nanopore Technologies Limited Adaptors for nucleic acid constructs in transmembrane sequencing
GB0905140D0 (en) 2009-03-25 2009-05-06 Isis Innovation Method
WO2012107778A2 (en) 2011-02-11 2012-08-16 Oxford Nanopore Technologies Limited Mutant pores
AU2012288629B2 (en) 2011-07-25 2017-02-02 Oxford Nanopore Technologies Limited Hairpin loop method for double strand polynucleotide sequencing using transmembrane pores
EP2836506B1 (en) 2012-04-10 2017-04-19 Oxford Nanopore Technologies Limited Mutant lysenin pores
US11155860B2 (en) 2012-07-19 2021-10-26 Oxford Nanopore Technologies Ltd. SSB method
GB201314695D0 (en) 2013-08-16 2013-10-02 Oxford Nanopore Tech Ltd Method
AU2014224432B2 (en) 2013-03-08 2019-10-24 Oxford Nanopore Technologies Limited Enzyme stalling method
GB201313477D0 (en) 2013-07-29 2013-09-11 Univ Leuven Kath Nanopore biosensors for detection of proteins and nucleic acids
GB201403096D0 (en) 2014-02-21 2014-04-09 Oxford Nanopore Tech Ltd Sample preparation method
EP3137490B1 (en) 2014-05-02 2021-01-27 Oxford Nanopore Technologies Limited Mutant pores
KR20170042794A (ko) 2014-09-01 2017-04-19 브이아이비 브이지더블유 돌연변이체 csgg 포어
US10266885B2 (en) 2014-10-07 2019-04-23 Oxford Nanopore Technologies Ltd. Mutant pores
GB201418159D0 (en) 2014-10-14 2014-11-26 Oxford Nanopore Tech Ltd Method
CN105837674A (zh) * 2016-03-08 2016-08-10 无限极（中国）有限公司 一种东方铃蟾多肽及其制备方法与应用
GB201609220D0 (en) 2016-05-25 2016-07-06 Oxford Nanopore Tech Ltd Method
GB201807793D0 (en) 2018-05-14 2018-06-27 Oxford Nanopore Tech Ltd Method

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4677193A (en) * 1985-02-22 1987-06-30 The Salk Institute For Biological Studies Peptides containing an aliphatic-aromatic ketone side chain
US5073624A (en) * 1985-04-09 1991-12-17 Administrators Of The Tulane Educational Fund Therapeutic decapeptides
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
AU618029B2 (en) * 1987-11-02 1991-12-12 Imperial Chemical Industries Plc Polypeptide compounds
WO1989009229A1 (en) * 1988-03-31 1989-10-05 Immunobiology Research Institute, Inc. Treatment of hiv viremic patients with thymopentin
EP0438519B1 (en) * 1988-10-14 1998-05-06 The Administrators of The Tulane Educational Fund Therapeutic peptides
US5244883A (en) * 1990-11-29 1993-09-14 The Administrators Of The Tulane Educational Fund Nonapeptide bombesin antagonists
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.

Also Published As

Publication number Publication date
CZ285997B6 (cs) 1999-12-15
NO320945B1 (no) 2006-02-20
IL110045A0 (en) 1994-10-07
CN1136915C (zh) 2004-02-04
NO954996L (no) 1995-12-08
RU2154492C2 (ru) 2000-08-20
FI113008B (fi) 2004-02-27
DK0703786T3 (da) 2002-05-27
EP0703786A1 (de) 1996-04-03
EP0703786B1 (de) 2002-02-13
PL312219A1 (en) 1996-04-01
SG52240A1 (en) 1998-09-28
FI956014A (fi) 1995-12-14
ES2172533T3 (es) 2002-10-01
CN1125400A (zh) 1996-06-26
UA41938C2 (uk) 2001-10-15
DE4320201A1 (de) 1995-01-12
HU9503605D0 (en) 1996-02-28
BR9406893A (pt) 1996-09-10
PL175580B1 (pl) 1999-01-29
ZA944347B (en) 1995-02-15
HUT73673A (en) 1996-09-30
ATE213164T1 (de) 2002-02-15
DE59410052D1 (de) 2002-03-21
WO1995000168A1 (de) 1995-01-05
FI956014A0 (fi) 1995-12-14
KR100352541B1 (ko) 2002-12-26
AU688315B2 (en) 1998-03-12
JPH08511784A (ja) 1996-12-10
PT703786E (pt) 2002-07-31
TW370532B (en) 1999-09-21
AU6564794A (en) 1995-01-17
US5985834A (en) 1999-11-16
CZ308995A3 (en) 1996-03-13
KR960703015A (ko) 1996-06-19
NO954996D0 (no) 1995-12-08

Similar Documents

Publication Publication Date Title
IL110045A (en) Pharmaceutical compositions containing oligopeptides for combating AIDS and ARC and for immune stimulation and certain such novel oligopeptides
GEP20043375B (en) APRIL-Receptor (BCMA) and Use Thereof
GEP20053473B (en) High Potency Dihydroergotamine Compositions
AU6628496A (en) Polyether block copolymer micellar compositions for targeting biological agents
IL136503A0 (en) Adamantane derivatives
PL340906A1 (en) Adamantane derivatives
MY125978A (en) Admantane derivatives
HK1002017A1 (en) Lyospheres comprising gonadotropin
AP9801392A0 (en) Concentrated antibody preparation.
GEP20063741B (en) Nonaryl-Heterocyclic NMDA/NR2B Antagonists
CA2153340A1 (fr) Application du riluzole dans le traitement de la maladie de parkinson et des syndromes parkinsoniens
AU1890295A (en) Piperidines and pyrrolidines
EP0663835A1 (en) USE OF PARATHORMONE, ITS BIOLOGICALLY ACTIVE FRAGMENTS AND RELATED PEPTIDES FOR THE TREATMENT OF PREGNANCY PROBLEMS.
AU5892399A (en) 1, 2, 4-triazole-3-thione compounds
AU8332791A (en) Oral pharmaceutical compositions containing melatonin
PL315127A1 (en) Deuterised biologically active substances for percutaneous administration
AU9731198A (en) Histogranin peptide and their analgesic use
AU3808795A (en) Water-soluble derivatives of epipodophyllotoxin, process for their preparation, their use as medicinal product and their intended use in anticancer treatments
EP0744176A3 (en) Methods for inhibiting bone loss
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
GEP20043377B (en) Pharmaceutical Complex
AU7941294A (en) Composition for the treatment or prevention of herpes
TW374085B (en) Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use
UA41326C2 (uk) Фармацевтична композиція для профілактики або лікування вірусних захворювань, засіб для профілактики або лікування вірусних захворювань
WO1998050397A3 (de) Chimäre oligonucleotide und ihre verwendung

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
HP Change in proprietorship
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees